Gene-drug interactions (data source: DGIdb)
Gene Name Entrez ID Drug Name Chembl ID Interaction Types Sources publications
OPRM1 4988 OXYCODONE CHEMBL656 agonist TdgClinicalTrial, ChemblInteractions, TEND
OPRM1 4988 NALOXONE HYDROCHLORIDE CHEMBL1718 antagonist ChemblInteractions
OPRM1 4988 DEZOCINE CHEMBL1685 partial agonist, agonist TdgClinicalTrial, ChemblInteractions, TEND, DrugBank 1361946, 12513698, 11702089, 9972766, 10958085, 9399970
OPRM1 4988 METHADYL ACETATE CHEMBL170179 agonist TdgClinicalTrial, TEND, DrugBank, TTD 6268422, 19153939, 20163389, 11752352
OPRM1 4988 DIACETYLMORPHINE CHEMBL459324 agonist DrugBank 15013161, 16580639, 12902992, 15937104, 15986196
OPRM1 4988 DIPRENORPHINE CHEMBL281786 antagonist GuideToPharmacologyInteractions, DrugBank 20641600
OPRM1 4988 METHYLNALTREXONE CHEMBL1186579 antagonist TdgClinicalTrial, GuideToPharmacologyInteractions, DrugBank, TTD 17504835
OPRM1 4988 CHEMBL561339 CHEMBL561339 agonist GuideToPharmacologyInteractions
OPRM1 4988 CEBRANOPADOL CHEMBL2364605 agonist GuideToPharmacologyInteractions, ChemblInteractions
OPRM1 4988 HYDROMORPHONE CHEMBL398707 agonist TdgClinicalTrial, GuideToPharmacologyInteractions, TEND
OPRM1 4988 TRAMADOL CHEMBL1237044 agonist TdgClinicalTrial, GuideToPharmacologyInteractions, TEND, TTD
OPRM1 4988 DADLE CHEMBL340032 agonist GuideToPharmacologyInteractions
OPRM1 4988 DYNORPHIN A (1-17) CHEMBL411557 agonist GuideToPharmacologyInteractions
OPRM1 4988 ENDOMORPHIN-1 CHEMBL316446 agonist GuideToPharmacologyInteractions
OPRM1 4988 ETONITAZENE CHEMBL312040 agonist GuideToPharmacologyInteractions
OPRM1 4988 CHEMBL283287 CHEMBL283287 agonist GuideToPharmacologyInteractions
OPRM1 4988 REL-PENTAZOCINE CHEMBL397705 agonist GuideToPharmacologyInteractions
OPRM1 4988 DEXAMETHASONE CHEMBL384467 allosteric modulator GuideToPharmacologyInteractions
OPRM1 4988 CHEMBL1797687 CHEMBL1797687 antagonist GuideToPharmacologyInteractions
OPRM1 4988 NALMEFENE CHEMBL982 antagonist TdgClinicalTrial, GuideToPharmacologyInteractions
OPRM1 4988 NALOXONE CHEMBL80 antagonist PharmGKB, TdgClinicalTrial, GuideToPharmacologyInteractions, TEND, TTD
OPRM1 4988 NALOXONE BENZOYLHYDRAZONE CHEMBL1256836 antagonist GuideToPharmacologyInteractions
OPRM1 4988 Naltalimide CHEMBL3545408 partial agonist ChemblInteractions
OPRM1 4988 MEPERIDINE HYDROCHLORIDE CHEMBL1701 agonist ChemblInteractions
OPRM1 4988 METHADONE HYDROCHLORIDE CHEMBL1200825 agonist ChemblInteractions
OPRM1 4988 ANILERIDINE HYDROCHLORIDE CHEMBL1201047 agonist ChemblInteractions
OPRM1 4988 TAPENTADOL HYDROCHLORIDE CHEMBL1201777 agonist ChemblInteractions
OPRM1 4988 HYDROCODONE POLISTIREX CHEMBL1201470 agonist ChemblInteractions
OPRM1 4988 CODEINE POLISTIREX CHEMBL1201463 agonist ChemblInteractions
OPRM1 4988 CODEINE PHOSPHATE HYDRATE CHEMBL1201099 agonist ChemblInteractions
OPRM1 4988 NALTREXONE HYDROCHLORIDE CHEMBL1201149 antagonist ChemblInteractions
OPRM1 4988 NALBUPHINE HYDROCHLORIDE CHEMBL1201132 agonist ChemblInteractions
OPRM1 4988 OXYMORPHONE CHEMBL963 agonist TdgClinicalTrial, TEND, TTD
OPRM1 4988 PENTAZOCINE CHEMBL560 TdgClinicalTrial, TEND
OPRM1 4988 CODEINE SULFATE CHEMBL284671 agonist ChemblInteractions
OPRM1 4988 DIFENOXIN HYDROCHLORIDE CHEMBL1200599 agonist ChemblInteractions
OPRM1 4988 ANILERIDINE PHOSPHATE CHEMBL1200543 agonist ChemblInteractions
OPRM1 4988 AXOMADOL CHEMBL2107731 agonist ChemblInteractions
OPRM1 4988 METHYLNALTREXONE BROMIDE CHEMBL1201770 antagonist TdgClinicalTrial, ChemblInteractions, TEND
OPRM1 4988 LEVALLORPHAN CHEMBL1254682 partial agonist, antagonist TdgClinicalTrial, GuideToPharmacologyInteractions, TEND, DrugBank 8819494, 9862398, 7723747, 8968334, 9016350
OPRM1 4988 DIPHENOXYLATE CHEMBL1201294 agonist TdgClinicalTrial, TEND, DrugBank 11752352, 18192961, 8583364, 8386327, 10202212
OPRM1 4988 ETHYLMORPHINE CHEMBL1712170 agonist DrugBank 11752352, 16682505, 16580848, 16530171, 16580639
OPRM1 4988 Buprenorphine Hydrochloride CHEMBL2368861 agonist ChemblInteractions, DrugBank, TTD
OPRM1 4988 KETOBEMIDONE CHEMBL47072 agonist DrugBank 8153059, 8878254
OPRM1 4988 LEVORPHANOL CHEMBL592 agonist TdgClinicalTrial, GuideToPharmacologyInteractions, TEND
OPRM1 4988 CHEMBL442577 CHEMBL442577 agonist GuideToPharmacologyInteractions
OPRM1 4988 DAMGO CHEMBL38874 agonist GuideToPharmacologyInteractions
OPRM1 4988 DYNORPHIN B CHEMBL500830 agonist GuideToPharmacologyInteractions
OPRM1 4988 ETHYLKETOCYCLAZOCINE CHEMBL279968 agonist GuideToPharmacologyInteractions
OPRM1 4988 NORMORPHINE CHEMBL1227 agonist GuideToPharmacologyInteractions
OPRM1 4988 SUFENTANIL CHEMBL658 agonist TdgClinicalTrial, GuideToPharmacologyInteractions, TEND
OPRM1 4988 CHEMBL507214 CHEMBL507214 antagonist GuideToPharmacologyInteractions
OPRM1 4988 GENETICIN CHEMBL215226 agonist, antagonist GuideToPharmacologyInteractions, TTD
OPRM1 4988 NALORPHINE CHEMBL415284 antagonist GuideToPharmacologyInteractions
OPRM1 4988 NORBINALTORPHIMINE CHEMBL573214 antagonist GuideToPharmacologyInteractions
OPRM1 4988 ZYKLOPHIN CHEMBL2372399 antagonist GuideToPharmacologyInteractions
OPRM1 4988 NALDEMEDINE CHEMBL2105755 antagonist ChemblInteractions
OPRM1 4988 OXYCODONE HYDROCHLORIDE CHEMBL1200890 agonist ChemblInteractions
OPRM1 4988 SUFENTANIL CITRATE CHEMBL1201163 agonist ChemblInteractions
OPRM1 4988 BUTORPHANOL TARTRATE CHEMBL299400 partial agonist ChemblInteractions
OPRM1 4988 NALMEFENE HYDROCHLORIDE CHEMBL1201152 antagonist ChemblInteractions
OPRM1 4988 HYDROCODONE BITARTRATE CHEMBL2062267 agonist ChemblInteractions
OPRM1 4988 CHEMBL1255944 CHEMBL1255944 antagonist TTD
OPRM1 4988 CHEMBL300662 CHEMBL300662 antagonist TTD
OPRM1 4988 AMPHETAMINE CHEMBL405 PharmGKB
OPRM1 4988 TRAMADOL HYDROCHLORIDE CHEMBL1237065 agonist ChemblInteractions
OPRM1 4988 LEVOMETHADYL ACETATE CHEMBL1514 agonist TdgClinicalTrial, TEND, DrugBank, TTD 9360954, 11752352, 11561100, 2471291, 10911931
OPRM1 4988 FENTANYL CITRATE CHEMBL688 agonist ChemblInteractions
OPRM1 4988 CARFENTANIL CHEMBL290429 agonist DrugBank 15001679, 14744466, 15028244, 1656846, 7957034
OPRM1 4988 DIHYDROMORPHINE CHEMBL1500 agonist GuideToPharmacologyInteractions, DrugBank 19474215, 16777416, 15178355
OPRM1 4988 TAPENTADOL CHEMBL1201776 agonist TdgClinicalTrial, GuideToPharmacologyInteractions, TEND, DrugBank 10592235
OPRM1 4988 ELUXADOLINE CHEMBL2159122 agonist GuideToPharmacologyInteractions, ChemblInteractions, DrugBank 23583433, 25261794
OPRM1 4988 PROPOXYPHENE NAPSYLATE CHEMBL1237085 agonist ChemblInteractions, DrugBank 10690289, 11752352, 6249436
OPRM1 4988 EDROPHONIUM CHEMBL1104 agonist GuideToPharmacologyInteractions
OPRM1 4988 LOPERAMIDE CHEMBL841 agonist TdgClinicalTrial, GuideToPharmacologyInteractions, TEND
OPRM1 4988 NALBUPHINE CHEMBL895 agonist TdgClinicalTrial, GuideToPharmacologyInteractions, TEND
OPRM1 4988 FENTANYL CHEMBL596 agonist TdgClinicalTrial, GuideToPharmacologyInteractions, ChemblInteractions, TEND, TTD
OPRM1 4988 NALTREXONE CHEMBL19019 antagonist TdgClinicalTrial, GuideToPharmacologyInteractions, ChemblInteractions, TEND
OPRM1 4988 NALTRINDOLE CHEMBL567175 antagonist GuideToPharmacologyInteractions
OPRM1 4988 QUADAZOCINE CHEMBL2111022 antagonist GuideToPharmacologyInteractions
OPRM1 4988 ALFENTANIL HYDROCHLORIDE CHEMBL1200531 agonist ChemblInteractions
OPRM1 4988 FENTANYL HYDROCHLORIDE CHEMBL1201159 agonist ChemblInteractions
OPRM1 4988 METHYLSAMIDORPHAN CHEMBL2364619 antagonist TdgClinicalTrial, ChemblInteractions
OPRM1 4988 REMIFENTANIL HYDROCHLORIDE CHEMBL1201120 agonist ChemblInteractions
OPRM1 4988 LEVOMETHADYL ACETATE HYDROCHLORIDE CHEMBL1200817 agonist ChemblInteractions
OPRM1 4988 CHEMBL140278 CHEMBL140278 TdgClinicalTrial
OPRM1 4988 ALFENTANIL CHEMBL634 agonist PharmGKB, TdgClinicalTrial, TEND, TTD
OPRM1 4988 AXELOPRAN CHEMBL3137313 antagonist TdgClinicalTrial, ChemblInteractions
OPRM1 4988 NALDEMEDINE TOSYLATE CHEMBL3039508 antagonist ChemblInteractions
OPRM1 4988 OXYCODONE TEREPHTHALATE CHEMBL1200611 agonist ChemblInteractions
OPRM1 4988 LEVORPHANOL TARTRATE CHEMBL2062261 agonist ChemblInteractions
OPRM1 4988 SAMIDORPHAN CHEMBL426084 antagonist TdgClinicalTrial, ChemblInteractions
OPRM1 4988 MORPHINE CHEMBL70 agonist TdgClinicalTrial, GuideToPharmacologyInteractions, TEND, DrugBank 11752352, 16682505, 16580848, 16530171, 16580639
OPRM1 4988 METHADONE CHEMBL651 agonist TdgClinicalTrial, GuideToPharmacologyInteractions, TEND, DrugBank 17850768, 17139284, 17016423, 11933204, 14991152
OPRM1 4988 PROPOXYPHENE HYDROCHLORIDE CHEMBL1237104 agonist ChemblInteractions, DrugBank 10690289, 6249436, 7562497, 11752352, 19604717, 10379623, 9399970
OPRM1 4988 REMIFENTANIL CHEMBL1005 agonist TdgClinicalTrial, TEND, DrugBank, TTD 9103501, 8694317, 11752352, 8875131, 16114980, 16332149, 9066316
OPRM1 4988 ANILERIDINE CHEMBL1201347 agonist TdgClinicalTrial, TEND, DrugBank, TTD 11752352, 17139284, 17016423
OPRM1 4988 CHEMBL2365680 CHEMBL2365680 agonist DrugBank 11752352, 16797997, 19403616, 16114980, 16332149, 16376082, 15589524
OPRM1 4988 DIMETHYLTHIAMBUTENE CHEMBL2106265 agonist DrugBank 13651575, 17139284, 17016423
OPRM1 4988 ETORPHINE (CHEMBL1908334) CHEMBL1908334 agonist GuideToPharmacologyInteractions, DrugBank 11098106, 11752352, 11420091, 11900797, 12435815, 10881033
OPRM1 4988 CHEMBL609728 CHEMBL609728 DrugBank
OPRM1 4988 ALVIMOPAN CHEMBL270190 antagonist TdgClinicalTrial, GuideToPharmacologyInteractions, ChemblInteractions, TEND, DrugBank, TTD 17909271, 11752352, 16597533, 11755894, 19086236, 15882122
OPRM1 4988 NALOXEGOL CHEMBL2219418 antagonist DrugBank 25471070
OPRM1 4988 CHEMBL25230 CHEMBL25230 agonist GuideToPharmacologyInteractions
OPRM1 4988 HYDROCODONE CHEMBL1457 agonist TdgClinicalTrial, GuideToPharmacologyInteractions, TEND
OPRM1 4988 CODEINE CHEMBL485 agonist TdgClinicalTrial, GuideToPharmacologyInteractions, TEND
OPRM1 4988 BUPRENORPHINE CHEMBL511142 agonist TdgClinicalTrial, GuideToPharmacologyInteractions, ChemblInteractions, TEND, TTD
OPRM1 4988 BUTORPHANOL CHEMBL33986 agonist TdgClinicalTrial, GuideToPharmacologyInteractions, TEND
OPRM1 4988 BNTX CHEMBL252172 antagonist GuideToPharmacologyInteractions
OPRM1 4988 CHEMBL1795717 CHEMBL1795717 antagonist GuideToPharmacologyInteractions
OPRM1 4988 ESMOLOL CHEMBL768 antagonist GuideToPharmacologyInteractions
OPRM1 4988 NALTRIBEN CHEMBL100940 antagonist GuideToPharmacologyInteractions
OPRM1 4988 HYDROMORPHONE HYDROCHLORIDE CHEMBL1237055 agonist ChemblInteractions
OPRM1 4988 LOPERAMIDE HYDROCHLORIDE CHEMBL1707 agonist ChemblInteractions
OPRM1 4988 DIPHENOXYLATE HYDROCHLORIDE CHEMBL1200665 agonist ChemblInteractions
OPRM1 4988 FRAKEFAMIDE CHEMBL2105081 agonist ChemblInteractions
OPRM1 4988 BEVENOPRAN CHEMBL3039511 antagonist ChemblInteractions
OPRM1 4988 OLICERIDINE CHEMBL2443262 agonist ChemblInteractions
OPRM1 4988 MORPHINE SULFATE HYDRATE CHEMBL2103744 agonist ChemblInteractions
OPRM1 4988 OXYMORPHONE HYDROCHLORIDE CHEMBL1200794 agonist ChemblInteractions
OPRM1 4988 PROPOXYPHENE CHEMBL1213351 TdgClinicalTrial, TEND
OPRM1 4988 BENZHYDROCODONE HYDROCHLORIDE CHEMBL3137310 TdgClinicalTrial
OPRM1 4988 ALCOHOL CHEMBL545 PharmGKB
OPRM1 4988 ODELEPRAN CHEMBL2103878 antagonist ChemblInteractions
OPRM1 4988 FAXELADOL CHEMBL2103829 agonist ChemblInteractions
OPRM1 4988 LEVALLORPHAN TARTRATE CHEMBL2062276 antagonist ChemblInteractions
OPRM1 4988 NALOXEGOL OXALATE CHEMBL2219416 antagonist ChemblInteractions
OPRM1 4988 DIHYDROCODEINE BITARTRATE CHEMBL2062266 agonist ChemblInteractions

Variant-drug associations (data source: PharmGKB)
Gene Name Variant Alleles Chemical Phenotype Category Significance Notes Sentence Publications Annotation ID
OPRM1 rs1799971 G codeine metabolism/PK no Post-mortem analysis of codeine-related deaths. No significant association between this variant and concentrations of codeine or morphine resulting from codeine metabolism. Allele G is not associated with concentrations of codeine or morphine as compared to allele A. 24747667 1451206853
OPRM1 rs1799971 G buprenorphine dosage no Genotype G is not associated with dose of buprenorphine, dihydrocodeine, fentanyl, hydromorphone, methadone, morphine, oxycodone, piritramide, tilidine or tramadol in people with Pain as compared to genotype A. 19514130 1451159083
OPRM1 rs1799971 AG + GG morphine dosage no Variant described as OPRM1 118A>G. Genotypes AG + GG is not associated with increased dose of morphine in infants as compared to genotype AA. 25155931 1184753725
OPRM1 rs1799971 AG + GG alfentanil dosage yes [stat_test: mann-whitney u-test]. Patient controlled analgesia. Genotypes AG + GG are associated with increased dose of alfentanil in people with Pain as compared to genotype AA. 19605407 827847849
OPRM1 rs1799971 AG + GG morphine efficacy yes Presence of the G allele was associated with higher pain scores in patients taking morphine. Otherwise healthy adolescents undergoing spinal fusion for scoliosis. Genotypes AG + GG is associated with decreased response to morphine in children as compared to genotype AA. 25266679 1445296785
OPRM1 rs1799971 G ethanol dosage yes The G allele was significantly associated with increased frequency and quantity of alcohol use in adolescents. Allele G is associated with increased dose of ethanol in children as compared to allele A. 22436571 1450814162
OPRM1 rs1799971 G ethanol dosage yes Adolescents carrying the G allele drank significantly more ethanol over a week than adolescents who did not carry the allele. Allele G is associated with increased dose of ethanol in children as compared to allele A. 22798433 1450814522
OPRM1 rs1799971 AG + GG ethanol dosage no No significant difference in alcohol consumption by adolescents in the AG + GG genotype group compared to AA. Genotypes AG + GG are not associated with dose of ethanol in children as compared to genotype AA. 24134200 1450820613
OPRM1 rs1799971 AA ethanol dosage yes Adolescents with the AA genotype showed a greater increase in alcohol use over the duration of the study than those carrying the G allele. Genotype AA is associated with increased dose of ethanol in children as compared to genotypes AG + GG. 25215437 1450821413
OPRM1 rs1799971 AG + GG morphine efficacy yes Genotypes AG + GG are associated with increased dose of morphine as compared to genotype AA. 17156920 731462495
OPRM1 rs10457090 G cotinine metabolism/PK yes Allele G is associated with increased concentrations of cotinine in people with Heroin Dependence as compared to allele A. 23223006 1449188418
OPRM1 rs10485057 G naltrexone efficacy no No significant association between this variant and smoking quit rate when naltrexone was used as augmentation to nicotine patch therapy. Allele G is not associated with response to naltrexone in people with Tobacco Use Disorder as compared to allele A. 31206155 1451113721
OPRM1 rs7776341 C morphine "dosage","efficacy" no No significant association between the individual variant and dose of morphine. However, the haplotype of seven OPRM1 variants studied in this paper was significantly associated with morphine dose requirements (p=0.002). Allele C is not associated with dose of morphine in people with Pain, Postoperative as compared to allele A. 26902643 1449295891
OPRM1 rs1323042 G opioids dosage no Variant had no significant association with opioid dose in either the development sample or the validation sample. Please note that alleles have been complemented to the positive strand. Allele G is not associated with dose of opioids in people with Pain as compared to allele T. 21398039 1449714658
OPRM1 rs1799971 AG + GG sufentanil efficacy no No significant difference in VAS pain scores between genotype groups. Genotypes AG + GG are not associated with response to sufentanil in people with Pain, Postoperative as compared to genotype AA. 31773688 1451134681
OPRM1 rs9479757 AA methadone "dosage","metabolism/PK" yes Genotype AA is not associated with increased dose of methadone in people with Heroin Dependence as compared to genotype GG. 21902500 827816385
OPRM1 rs1799971 GG morphine "dosage","efficacy" yes Genotype GG is associated with increased dose of morphine in people with Pain, Postoperative as compared to genotypes AA + AG. 16879459 1449188852
OPRM1 rs677830 T morphine "dosage","efficacy" no No significant association between the individual variant and dose of morphine. However, the haplotype of seven OPRM1 variants studied in this paper was significantly associated with morphine dose requirements (p=0.002). A stepwise backward linear regression model of age, rs9340799, rs1799971, rs4986936, rs1319339, rs174696, rs677830, rs4680, rs4818, and rs540825 was found to explain 10.7% of variance in morphine dose requirements in the study cohort (p=0.001) Allele T is not associated with dose of morphine in people with Pain, Postoperative as compared to allele C. 26902643 1449295915
OPRM1 rs671531 GG highly active antiretroviral therapy efficacy yes Patients with the GG genotype showed no decrease in viral load following the initiation of HAART, while patients with the AA or AG genotypes had a decrease in viral load. This association was only found in Hispanic patients. Genotype GG is associated with decreased response to highly active antiretroviral therapy (haart) in people with HIV Infections as compared to genotypes AA + AG. 22457278 1450814181
OPRM1 rs2236258 C methadone efficacy no This SNP was not significantly associated with compliance with methadone maintenance therapy or 'negative rate of morphine urine test'. Allele C is not associated with response to methadone in people with Heroin Dependence as compared to allele T. 30420869 1450373190
OPRM1 rs2236259 C methadone efficacy no This SNP was not significantly associated with compliance with methadone maintenance therapy or 'negative rate of morphine urine test'. Allele C is not associated with response to methadone in people with Heroin Dependence as compared to allele T. 30420869 1450373197
OPRM1 rs6902403 C methadone efficacy no This SNP was not significantly associated with compliance with methadone maintenance therapy or 'negative rate of morphine urine test'. Allele C is not associated with response to methadone in people with Heroin Dependence as compared to allele T. 30420869 1450373204
OPRM1 rs9479757 A opioids dosage no Variant had no significant association with opioid dose in either the development sample or the validation sample. Allele A is not associated with dose of opioids in people with Pain as compared to allele G. 21398039 1449714630
OPRM1 rs540825 T morphine "dosage","efficacy" no No significant association between the individual variant and dose of morphine. However, the haplotype of seven OPRM1 variants studied in this paper was significantly associated with morphine dose requirements (p=0.002). A stepwise backward linear regression model of age, rs9340799, rs1799971, rs4986936, rs1319339, rs174696, rs677830, rs4680, rs4818, and rs540825 was found to explain 10.7% of variance in morphine dose requirements in the study cohort (p=0.001) Allele T is not associated with dose of morphine in people with Pain, Postoperative as compared to allele A. 26902643 1449295909
OPRM1 rs1799971 A cotinine metabolism/PK yes Allele A is associated with increased concentrations of cotinine in people with Heroin Dependence as compared to allele G. 23223006 1449188368
OPRM1 rs3823010 A naltrexone efficacy no No significant association between this variant and smoking quit rate when naltrexone was used as augmentation to nicotine patch therapy. Allele A is not associated with response to naltrexone in people with Tobacco Use Disorder as compared to allele G. 31206155 1451113812
OPRM1 rs1799971 GG morphine dosage no Genotype GG is associated with increased dose of morphine in women with Pain, Postoperative as compared to genotypes AA + AG. 24703092 1449162954
OPRM1 rs675026 G methadone efficacy no This SNP was not significantly associated with compliance with methadone maintenance therapy or 'negative rate of morphine urine test'. Please note that alleles have been complemented to the positive strand. Allele G is not associated with response to methadone in people with Heroin Dependence as compared to allele A. 30420869 1450373150
OPRM1 rs548646 C opioids dosage no Variant had no significant association with opioid dose in either the development sample or the validation sample. Allele C is not associated with dose of opioids in people with Pain as compared to allele T. 21398039 1449714651
OPRM1 rs497976 G opioids dosage no Variant had no significant association with opioid dose in either the development sample or the validation sample. Please note that alleles have been complemented to the positive strand. Allele G is not associated with dose of opioids in people with Pain as compared to allele T. 21398039 1449714679
OPRM1 rs3798676 T cotinine metabolism/PK yes Allele T is associated with increased concentrations of cotinine in people with Heroin Dependence as compared to allele C. 23223006 1449188388
OPRM1 rs553202 T cotinine metabolism/PK yes Allele T is associated with increased concentrations of cotinine in people with Heroin Dependence as compared to allele C. 23223006 1449188394
OPRM1 rs7748401 G cotinine metabolism/PK yes Allele G is associated with increased concentrations of cotinine in people with Heroin Dependence as compared to allele T. 23223006 1449188406
OPRM1 rs495491 G cotinine metabolism/PK yes Please note that alleles have been complemented to the positive strand. Allele G is associated with increased concentrations of cotinine in people with Heroin Dependence as compared to allele A. 23223006 1449188412
OPRM1 rs511435 T naltrexone efficacy no No significant association between this variant and smoking quit rate when naltrexone was used as augmentation to nicotine patch therapy. This is a C/G/T SNP. Based on allele frequencies reported in dbSNP, it is assumed that the major allele in this study is C and the minor allele is T. Please note that alleles have been complemented to the positive strand. Allele T is not associated with response to naltrexone in people with Tobacco Use Disorder as compared to allele C. 31206155 1451113825
OPRM1 rs1381376 A naltrexone efficacy no No significant association between this variant and smoking quit rate when naltrexone was used as augmentation to nicotine patch therapy. Note that this is a A/C/G/T SNP. Based on allele frequencies reported by dbSNP, it is assumed that the major allele in this study is C and the minor allele is A. Please note that alleles have been complemented to the positive strand. Allele A is not associated with response to naltrexone in people with Tobacco Use Disorder as compared to allele C. 31206155 1451113800
OPRM1 rs1799971 G nalmefene efficacy no Allele G is not associated with response to nalmefene in people with Alcoholism as compared to allele A. 18537939 1449161492
OPRM1 rs1799971 AG morphine dosage yes The setting was for palliative care of cancer patients. Genotype AG is associated with increased dose of morphine in people with Neoplasms as compared to genotype AA. 28346387 1448612958
OPRM1 rs1799971 GG fentanyl "dosage","efficacy" yes Genotype GG is associated with increased dose of fentanyl in women with Pain, Postoperative as compared to genotypes AA + AG. 20003118 1449716606
OPRM1 rs1799971 AG + GG fentanyl efficacy no Duration of fentanyl analgesia was similar between the genotype groups. Genotypes AG + GG are not associated with response to fentanyl in women with Pain as compared to genotype AA. 20171873 1449716512
OPRM1 rs558025 AG + GG methadone dosage no This association was not statistically significant after permutation analysis based on 40,000 replicates, and not statistically significant after adjusting for testing for multiple SNPs (Bonferroni correction). Note; this SNP is in LD with rs660756 (r^2>0.7). Genotypes AG + GG are associated with decreased dose of methadone in people with Heroin Dependence as compared to genotype AA. 23651024 982032649
OPRM1 rs1799971 G morphine efficacy no No significant difference in improvement in pain scores between genotype groups. Allele G is not associated with response to morphine and nortriptyline in people with Pain as compared to allele A. 31738228 1451133680
OPRM1 rs1799971 AG + GG oxycodone efficacy yes Patients with the GG genotype had increased VAS pain scores compared to the AA and AG genotypes at 4/6 timepoints, while both the AG and GG genotypes had increased VAS pain scores compared to the AA genotype at 2/6 timepoints. Genotypes AG + GG are associated with decreased response to oxycodone in people with Pain, Postoperative as compared to genotype AA. 31773688 1451134629
OPRM1 rs1799971 AG + GG oxycodone dosage no No significant difference in total dosage of oxycodone or sufentanil between genotype groups. Genotypes AG + GG are not associated with dose of oxycodone or sufentanil in people with Pain, Postoperative as compared to genotype AA. 31773688 1451134687
OPRM1 rs1799971 AG + GG sufentanil dosage yes Patients with the GG genotype had significantly increased sufentanil consumption compared to patients with the AA or AG genotypes, while those with the AG genotype had significantly increased compared to patients with the AA genotype. Genotypes AG + GG are associated with increased dose of sufentanil in people with Lung Neoplasms and Pain, Postoperative as compared to genotype AA. 30455395 1450931989
OPRM1 rs1323040 AG + GG sufentanil dosage yes Patients with the GG genotype had significantly increased sufentanil consumption compared to patients with the AA or AG genotypes, while those with the AG genotype had significantly increased compared to patients with the AA genotype. Genotypes AG + GG are associated with increased dose of sufentanil in people with Lung Neoplasms and Pain, Postoperative as compared to genotype AA. 30455395 1450931998
OPRM1 rs563649 C sufentanil dosage no No significant association between this variant and consumption of sufentanil. While this variant is described in the text as a C>T SNP, it is displayed in the table as a G>A SNP. dbSNP confirms that this is a C>T SNP so it has been assumed that this is an error in the tables. As a result, information from the tables has been assigned to the following genotypes: AA=CC, AG=CT and GG=TT. Allele C is not associated with dose of sufentanil in people with Lung Neoplasms and Pain, Postoperative as compared to allele T. 30455395 1450932030
OPRM1 rs12205732 A methadone dosage no No significant difference in allele or genotype frequencies between patients taking >45mg of methadone per day and those taking <45mg methadone per day. Allele A is not associated with dose of methadone in people with Heroin Dependence as compared to allele G. 31940240 1451138741
OPRM1 rs6912029 T methadone dosage no No significant difference in allele or genotype frequencies between patients taking >45mg of methadone per day and those taking <45mg methadone per day. Allele T is not associated with dose of methadone in people with Heroin Dependence as compared to allele G. 31940240 1451138747
OPRM1 rs9322453 C methadone dosage no No significant difference in allele or genotype frequencies between patients taking >45mg of methadone per day and those taking <45mg methadone per day. Allele C is not associated with dose of methadone in people with Heroin Dependence as compared to allele G. 31940240 1451138753
OPRM1 rs9322453 C heroin dosage no No significant difference in allele or genotype frequencies between patients who reported taking >0.5g of heroin per day and those who reported taking <0.5g heroin per day. Allele C is not associated with dose of heroin in people with Heroin Dependence as compared to allele G. 31940240 1451138802
OPRM1 rs6912029 T heroin dosage no No significant difference in allele or genotype frequencies between patients who reported taking >0.5g of heroin per day and those who reported taking <0.5g heroin per day. Allele T is not associated with dose of heroin in people with Heroin Dependence as compared to allele G. 31940240 1451138797
OPRM1 rs12205732 A heroin dosage no No significant difference in allele or genotype frequencies between patients who reported taking >0.5g of heroin per day and those who reported taking <0.5g heroin per day. Allele A is not associated with dose of heroin in people with Heroin Dependence as compared to allele G. 31940240 1451138791
OPRM1 rs1799971 A buprenorphine efficacy no Please note that genotypes have been complemented to the positive strand. Allele A is not associated with response to buprenorphine in people with Ischemia and Pain as compared to allele G. 26407542 1449147581
OPRM1 rs1799971 G naltrexone efficacy no No significant association between the variant and drinking outcomes following correction for multiple comparisons. A meta-analysis combined all outcomes measured also found no significant association with the variant. Allele G is not associated with response to naltrexone in people with Alcoholism as compared to allele A. 31961981 1451141783
OPRM1 rs1799971 G naltrexone efficacy no There was no significant main effect of rs1799971 genotype on alcohol craving or consumption during naltrexone treatment. However, the authors found that the G allele significantly moderated the interaction between adherence to naltrexone and same-day alcohol consumption. Allele G is not associated with response to naltrexone in people with Alcoholism as compared to allele A. 32020635 1451143900
OPRM1 rs1799971 G ketamine efficacy no No significant difference in changes in MADRS scores on days 2 or 28 of treatment with ketamine and an oral antidepressant compared to treatment with a placebo and an oral antidepressant. Allele G is not associated with response to ketamine in people with Depressive Disorder, Major as compared to allele A. 32367114 1451147820
OPRM1 rs648893 G ethanol efficacy no Please note that alleles have been complemented to the positive strand. No significant association between this variant and any individual item or total score on the Subjective High Assessment Scale-Expectations (SHAS-E) questionnaire. Allele G is not associated with response to ethanol as compared to allele A. 18433502 1450811804
OPRM1 rs648893 G naltrexone efficacy no No significant association between this variant and smoking quit rate when naltrexone was used as augmentation to nicotine patch therapy. Allele G is not associated with response to naltrexone in people with Tobacco Use Disorder as compared to allele A. 31206155 1451113880
OPRM1 rs3778152 G cotinine metabolism/PK yes Allele G is associated with increased concentrations of cotinine in people with Heroin Dependence as compared to allele A. 23223006 1449188430
OPRM1 rs9384179 AA fentanyl "dosage","efficacy" yes A formula was developed to predict individual opioid use during the first 24-h post-operative period for patients who underwent craniofacial surgery. The post-operative period R squared values were higher when genotype information was included. In the first group fentanyl was administered by IV, on demand, with a bolus dose of 20 micrograms and a 10 minute lockout period 24-h post-op. Genotype AA is associated with increased dose of fentanyl in people with Pain, Postoperative as compared to genotypes AG + GG. 25615449 1444693992
OPRM1 rs642489 T ethanol efficacy no Please note that alleles have been complemented to the positive strand. No significant association between this variant and any individual item or total score on the Subjective High Assessment Scale-Expectations (SHAS-E) questionnaire. Allele T is not associated with response to ethanol as compared to allele G. 18433502 1450811823
OPRM1 rs10485058 AA methadone efficacy yes Methadone patients with the AA genotype were less likely to have opioid-positive urine drug screens as compared to those with the AG and GG genotypes over 24 weeks. This SNP was not associated with response to buprenorphine treatment. A separate cohort of patients (CATS) was also analyzed; this cohort collected self-reported data on ever having had a relapse after a period of abstinence in opioid-dependent individuals. In this cohort, using an additive model, the A allele was found to be significantly associated with never having relapsed. Genotype AA is associated with increased response to methadone in people with Opioid-Related Disorders as compared to genotypes AG + GG. 27958381 1448526016
OPRM1 rs10485058 AA buprenorphine efficacy no No significant difference in the percentage of opioid-positive urine drug screens over 24 weeks was seen between patients with the AA and AG+GG genotypes. This SNP was associated with response to methadone treatment. Genotype AA is not associated with response to buprenorphine in people with Opioid-Related Disorders as compared to genotypes AG + GG. 27958381 1448526029
OPRM1 rs506247 C ethanol efficacy no Please note that alleles have been complemented to the positive strand. No significant association between this variant and any individual item or total score on the Subjective High Assessment Scale-Expectations (SHAS-E) questionnaire. Allele C is not associated with response to ethanol as compared to allele A. 18433502 1450811764
OPRM1 rs1799971 AA opioids "dosage","efficacy" yes No significant difference in dosage was seen in AA compared to AG or GG, or in AA compared to AG. Genotype AA is associated with decreased dose of opioids in people with Pain, Postoperative as compared to genotype GG. 28379874 1449002543
OPRM1 rs1799971 AG + GG fentanyl dosage yes Genotypes AG + GG are associated with decreased dose of fentanyl in women with Pain as compared to genotype AA. 23909491 1449716064
OPRM1 rs1799971 AG + GG opioids "dosage","efficacy" yes 24 hour dose of opioids was significantly increased in cancer pain patients with the AG or GG genotypes compared to patients with the AA genotype. Genotypes AG + GG are associated with increased dose of opioids in people with Neoplasms and Pain as compared to genotype AA. 23803057 1449713808
OPRM1 rs1799971 G fentanyl efficacy no No significant effect of this variant on the duration of fentanyl analgesia in laboring women. Allele G is not associated with response to fentanyl in women with Pain as compared to allele A. 23592691 1449713797
OPRM1 rs510769 T cotinine metabolism/PK yes Please note that alleles have been complemented to the positive strand Allele T is associated with increased concentrations of cotinine in people with Heroin Dependence as compared to allele C. 23223006 1449188382
OPRM1 rs17174629 G morphine "dosage","efficacy" no No association was observed between this variant and a patient's initial dose requirement or their need to escalate their dose of morphine. Allele G is not associated with dose of morphine in people with Pain as compared to allele A. 29259946 1449182316
OPRM1 rs1074287 G cotinine metabolism/PK yes Allele G is associated with increased concentrations of cotinine in people with Heroin Dependence as compared to allele A. 23223006 1449188355
OPRM1 rs1799972 T morphine "dosage","efficacy" no No association was observed between this variant and a patient's initial dose requirement or their need to escalate their dose of morphine. Allele T is not associated with dose of morphine in people with Pain as compared to allele C. 29259946 1449182334
OPRM1 rs6912029 T cotinine metabolism/PK yes Allele T is associated with increased concentrations of cotinine in people with Heroin Dependence as compared to allele G. 23223006 1449188362
OPRM1 rs12209447 T cotinine metabolism/PK yes Allele T is associated with increased concentrations of cotinine in people with Heroin Dependence as compared to allele C. 23223006 1449188376
OPRM1 rs499796 G cotinine metabolism/PK no Please note that alleles have been complemented to the positive strand. Allele G is not associated with concentrations of cotinine in people with Heroin Dependence as compared to allele A. 23223006 1449188400
OPRM1 rs1799971 G fentanyl dosage no No significant difference in 24 hour or 48 hour fentanyl consumption between genotype groups. Allele G is not associated with dose of fentanyl in women with Pain, Postoperative as compared to allele A. 23557865 1449713980
OPRM1 rs589046 T cotinine metabolism/PK yes Please note that alleles have been complemented to the positive strand. Allele T is associated with increased concentrations of cotinine in people with Heroin Dependence as compared to allele C. 23223006 1449188424
OPRM1 rs2075572 G cotinine metabolism/PK yes Note that while a significant association was seen when the additive model was used, this significance was lost when the recessive model was used. Allele G is associated with increased concentrations of cotinine in people with Heroin Dependence as compared to allele C. 23223006 1449188442
OPRM1 rs563649 T cotinine metabolism/PK yes Please note that alleles have been complemented to the positive strand. Allele T is associated with increased concentrations of cotinine in people with Heroin Dependence as compared to allele C. 23223006 1449188436
OPRM1 rs1799971 G opioids dosage no Variant had no significant association with opioid dose in either the development sample or the validation sample. Allele G is not associated with dose of opioids in people with Pain as compared to allele A. 21398039 1449714623
OPRM1 rs1799971 AG + GG naltrexone efficacy yes Carriers of the G allele have decreased relapse rates as compared to patients with the AA genotype. No difference seen in abstinence rates between different genotypes. Genotypes AG + GG are associated with increased response to naltrexone in people with Alcoholism as compared to genotype AA. 22515274 1449181636
OPRM1 rs1799971 AG opioids efficacy yes Patients were treated with tramadol, morphine, fentanyl or sufentanil. Pain was measured using visual analog scale (VAS) scores. Patients with the AG genotype had higher pain scores on standard doses of opioids than patients with the AA genotype. Genotype AG is associated with decreased response to opioids in people with Pain, Postoperative as compared to genotype AA. 22230405 1449271593
OPRM1 rs1319339 C morphine "dosage","efficacy" no No significant association between the individual variant and dose of morphine. However, the haplotype of seven OPRM1 variants studied in this paper was significantly associated with morphine dose requirements (p=0.002). A stepwise backward linear regression model of age, rs9340799, rs1799971, rs4986936, rs1319339, rs174696, rs677830, rs4680, rs4818, and rs540825 was found to explain 10.7% of variance in morphine dose requirements in the study cohort (p=0.001) Allele C is not associated with dose of morphine in people with Pain, Postoperative as compared to allele T. 26902643 1449295885
OPRM1 rs563649 C morphine "dosage","efficacy" no No significant association between the individual variant and dose of morphine. However, the haplotype of seven OPRM1 variants studied in this paper was significantly associated with morphine dose requirements (p=0.002). Allele C is not associated with dose of morphine in people with Pain, Postoperative as compared to allele T. 26902643 1449295897
OPRM1 rs2075572 G morphine "dosage","efficacy" no No significant association between the individual variant and dose of morphine. However, the haplotype of seven OPRM1 variants studied in this paper was significantly associated with morphine dose requirements (p=0.002). Allele G is not associated with dose of morphine in people with Pain, Postoperative as compared to allele C. 26902643 1449295903
OPRM1 rs1799971 GG Opioid anesthetics efficacy yes The GG genotype was significantly associated with a shorter recovery time from general anesthesia compared to the AA and AG genotypes. Genotype GG is associated with increased response to Opioid anesthetics, Other general anesthetics or volatile anesthetics as compared to genotypes AA + AG. 30136624 1449717924
OPRM1 rs1799971 G sufentanil dosage yes Allele G is associated with decreased dose of sufentanil in women with Pain as compared to allele A. 22153130 1449171287
OPRM1 rs540825 A opioids dosage no Variant had no significant association with opioid dose in either the development sample or the validation sample. It has been assumed based on the allele frequencies given in the paper that the reported alleles are on the negative strand, as a result, please note that the alleles have been complemented to the positive strand. Allele A is not associated with dose of opioids in people with Pain as compared to allele T. 21398039 1449714637
OPRM1 rs562859 C opioids dosage no Variant had no significant association with opioid dose in either the development sample or the validation sample. Please note that alleles have been complemented to the positive strand. Allele C is not associated with dose of opioids in people with Pain as compared to allele T. 21398039 1449714644
OPRM1 rs618207 C opioids dosage no Variant had no significant association with opioid dose in either the development sample or the validation sample. Allele C is not associated with dose of opioids in people with Pain as compared to allele T. 21398039 1449714665
OPRM1 rs639855 C opioids dosage no Variant had no significant association with opioid dose in either the development sample or the validation sample. Please note that alleles have been complemented to the positive strand. Allele C is not associated with dose of opioids in people with Pain as compared to allele A. 21398039 1449714672
OPRM1 rs1799971 G morphine metabolism/PK no Allele G is not associated with concentrations of morphine in people with Pain, Postoperative as compared to allele A. 29474345 1449173387
OPRM1 rs1799971 GG methadone efficacy no Genotype GG is not associated with response to methadone in people with Substance-Related Disorders as compared to genotypes AA + AG. 18687376 1449271133
OPRM1 rs1799971 GG methadone dosage no Genotype GG is not associated with dose of methadone in people with Substance-Related Disorders as compared to genotypes AA + AG. 18687376 1449271127
OPRM1 rs648893 G nalmefene efficacy no Allele G is not associated with response to nalmefene in people with Alcoholism as compared to allele A. 18537939 1449161507
OPRM1 rs1799971 AG + GG ethanol other no No significant associations between this variant and reported sensitivity to alcohol overall, during the last three-month period of drinking, during the participants' first five drinking episodes or at the period of heaviest drinking in their lives; or with reported or experimental sensitivity to the sedating or stimulatory effects of alcohol or subjective intoxication. Genotypes AG + GG are not associated with response to ethanol as compared to genotype AA. 28273335 1450824374
OPRM1 rs3778150 CC + CT ethanol yes Individuals carrying the C allele showed decreased reported sensitivity to alcohol overall, during the last three-month period of drinking and at the period of heaviest drinking in their lives compared to individuals with the TT genotype. C allele carriers also showed lower reported sensitivity to the sedating effects of alcohol and experimental alcohol stimulation compared to TT subjects. However, there was no significant association between this variant and reported alcohol sensitivity during the participants' first five drinking episodes, reported sensitivity to the stimulating effects of alcohol, experimental alcohol-related sedation or subjective intoxication. Genotypes CC + CT are associated with decreased response to ethanol as compared to genotype TT. 28273335 1450824235
OPRM1 rs10485057 AA nicotine dosage no Subjects with the AA genotype had increased tobacco consumption, but this association failed to meet statistical significance. Genotype AA is associated with increased dose of nicotine as compared to genotypes AG + GG. 26042510 1450822141
OPRM1 rs1799971 G nicotine efficacy no There was no significant difference in subjective reward from nicotine between the genotype groups. Allele G is not associated with response to nicotine as compared to allele A. 21576462 1450812933
OPRM1 rs10485057 AA ethanol dosage yes Subjects with the AA genotype has a significantly increased pure alcohol intake and were significantly more likely to be alcohol consumers compared to subjects with the AG genotype. Genotype AA is associated with increased dose of ethanol as compared to genotype AG. 26042510 1450822133
OPRM1 rs510769 T nicotine dosage no No significant association between this variant and tobacco consumption. Allele T is not associated with dose of nicotine as compared to allele C. 26042510 1450822109
OPRM1 rs1799971 G ethanol efficacy no No significant association between this variant and any individual item or total score on the Subjective High Assessment Scale-Expectations (SHAS-E) questionnaire. Allele G is not associated with response to ethanol as compared to allele A. 18433502 1450811650
OPRM1 rs648007 A ethanol efficacy yes Please note that alleles have been complemented to the positive strand. The A allele was associated with increased scores in the dizzy and nausea traits on the Subjective High Assessment Scale-Expectations (SHAS-E) questionnaire. Allele A is associated with increased response to ethanol as compared to allele G. 18433502 1450811896
OPRM1 rs1799971 G prochlorperazine efficacy no No significant difference in incidence of vomiting between genotype groups when treated with prochlorperazine for opioid-induced nausea and vomiting. Allele G is not associated with response to prochlorperazine in people with Vomiting as compared to allele A. 24360851 1450820835
OPRM1 rs1799971 G naltrexone efficacy no No significant medication x genotype interactions on alcohol craving, subjective response to alcohol or alcohol self-administration. Allele G is not associated with response to naltrexone as compared to allele A. 29265379 1450928668
OPRM1 rs1799971 G ethanol other no No significant main effect of this variant or interaction effect between this variant and social drinking condition on alcohol consumption in a controlled setting or blood alcohol content. Allele G is not associated with dose of ethanol as compared to allele A. 28992386 1450928634
OPRM1 rs553202 T ethanol efficacy yes Please note that alleles have been complemented to the positive strand. The T allele was associated with increased scores in the dizzy, drunk, high, nausea, terrible and uncomfortable traits on the Subjective High Assessment Scale-Expectations (SHAS-E) questionnaire. Allele T is associated with increased response to ethanol as compared to allele C. 18433502 1450811671
OPRM1 rs3778148 T ethanol efficacy yes The T allele was associated with increased scores in the dizzy, drunk, high, nausea, talkative and uncomfortable traits as well as increased total score on the Subjective High Assessment Scale-Expectations (SHAS-E) questionnaire. Allele T is associated with increased response to ethanol as compared to allele G. 18433502 1450811713
OPRM1 rs548646 T ethanol efficacy yes The T allele was associated with increased scores in the buzzed, clumsy and dizzy traits as well as increased total score on the Subjective High Assessment Scale-Expectations (SHAS-E) questionnaire. Allele T is associated with increased response to ethanol as compared to allele C. 18433502 1450811875
OPRM1 rs1461773 A ethanol efficacy yes Please note that alleles have been complemented to the positive strand. The T allele was associated with increased scores in the dizzy, drunk, high, nausea, talkative and uncomfortable traits as well as increased total score on the Subjective High Assessment Scale-Expectations (SHAS-E) questionnaire. Allele A is associated with increased response to ethanol as compared to allele G. 18433502 1450811735
OPRM1 rs9479757 AG heroin dosage yes Heroin-dependent patients with the AG genotype had a significantly higher daily intake of heroin compared to patients with the GG genotype. Genotype AG is associated with increased dose of heroin in people with Heroin Dependence as compared to genotype GG. 11933204 1450808090
OPRM1 rs1799971 AG + GG naltrexone efficacy no A meta-analysis of studies reporting outcome data for return to any drinking or return to heavy drinking found no significant difference in response between genotype groups. Genotypes AG + GG are not associated with response to naltrexone in people with Alcoholism as compared to genotype AA. 25410894 1450821424
OPRM1 rs1799971 G modafinil efficacy no No significant association between this variant and Treatment Effectiveness Scores following modafinil treatment compared to placebo. Allele G is not associated with response to modafinil in people with methamphetamine dependence as compared to allele A. 22217949 1450813982
OPRM1 rs510769 T ethanol dosage no No significant association between this variant and alcohol consumption. Allele T is not associated with dose of ethanol as compared to allele C. 26042510 1450822114
OPRM1 rs3778150 CC + CT ethanol dosage yes Subjects carrying the C allele had significantly higher drinking levels compared to individuals with the TT genotype. Genotypes CC + CT are associated with increased dose of ethanol as compared to genotype TT. 28273335 1450824458
OPRM1 rs681243 T ethanol efficacy yes Please note that alleles have been complemented to the positive strand. The T allele was associated with increased scores in the buzzed, clumsy, dizzy and nausea traits as well as increased total score on the Subjective High Assessment Scale-Expectations (SHAS-E) questionnaire. Allele T is associated with increased response to ethanol as compared to allele C. 18433502 1450811918
OPRM1 rs524731 A ethanol efficacy yes The A allele was associated with increased scores in the dizzy, drunk, high and terrible traits on the Subjective High Assessment Scale-Expectations (SHAS-E) questionnaire. Allele A is associated with increased response to ethanol as compared to allele C. 18433502 1450811690
OPRM1 rs563649 T ethanol efficacy no Please note that alleles have been complemented to the positive strand. No significant association between this variant and any individual item or total score on the Subjective High Assessment Scale-Expectations (SHAS-E) questionnaire. Allele T is not associated with response to ethanol as compared to allele C. 18433502 1450811783
OPRM1 rs1799971 G ethanol dosage no No significant interaction of OPRM1 with alcohol use in adolescents Allele G is not associated with dose of ethanol as compared to allele A. 22260295 1450814114
OPRM1 rs1799971 G ethanol dosage no No significant association between this variant and alcohol consumption. Allele G is not associated with dose of ethanol as compared to allele A. 23729673 1450820267
OPRM1 rs3192723 CC methadone efficacy no Patients with the CC genotype had a lower 'negative rate of morphine urine test' than patients with the CT or TT genotypes. However, this SNP was not significantly associated with MMT compliance in the study. Note that although this variant is located in MTRF1L, it is discussed in the paper as being an OPRM1 SNP. Please note that alleles have been complemented to the positive strand. Genotype CC is associated with decreased response to methadone in people with Heroin Dependence as compared to genotypes CT + TT. 30420869 1450373239
OPRM1 rs6912029 G methadone efficacy no This SNP was not significantly associated with compliance with methadone maintenance therapy or 'negative rate of morphine urine test'. Allele G is not associated with response to methadone in people with Heroin Dependence as compared to allele T. 30420869 1450373168
OPRM1 rs2236256 C methadone efficacy no This SNP was not significantly associated with compliance with methadone maintenance therapy or 'negative rate of morphine urine test'. Allele C is not associated with response to methadone in people with Heroin Dependence as compared to allele A. 30420869 1450373174
OPRM1 rs562859 TT methadone efficacy yes Although this SNP initially showed a significant association with both MMT compliance and 'negative rate of morphine urine test', significance in both associations was lost following adjusting for age, sex and methadone dosage. Note that although this variant is located in MTRF1L, it is discussed in the paper as being an OPRM1 SNP. Please note that alleles have been complemented to the positive strand. Genotype TT is not associated with response to methadone in people with Heroin Dependence as compared to genotypes CC + CT. 30420869 1450373158
OPRM1 rs2236257 C methadone efficacy no This SNP was not significantly associated with compliance with methadone maintenance therapy or 'negative rate of morphine urine test'. Allele C is not associated with response to methadone in people with Heroin Dependence as compared to allele G. 30420869 1450373183
OPRM1 rs1799971 AA + AG buprenorphine efficacy no Response defined by changes in the rate of dropout from treatment between genotypes. Genotypes AA + AG is not associated with response to buprenorphine or methadone in people with Opioid-Related Disorders as compared to genotype AA. 29333880 1449271245
OPRM1 rs1799971 G morphine dosage no Morphine concentrations were only able to be measured in one patient with the GG genotype. Allele G is associated with increased concentrations of morphine in women with Pain, Postoperative as compared to allele A. 24703092 1449162966
OPRM1 rs1799971 AG + GG ethanol other no No significant difference in amount of drinks consumed or hazardous drinking score between participants carrying the G allele and those with the AA genotype. Genotypes AG + GG are not associated with exposure to ethanol in healthy individuals as compared to genotype AA. 25836994 1450821908
OPRM1 rs1799971 A naltrexone efficacy no It should be noted that no overall effect of naltrexone treatment on alcohol consumption was observed. The authors suggest that this may be due to differences in the study cohort, bias or a type II error. Allele A is not associated with response to naltrexone in people with Alcoholism as compared to allele G. 22551036 1449161179
OPRM1 rs1799971 AG + GG fentanyl efficacy yes Genotypes AG + GG are associated with increased response to fentanyl in women with Pain as compared to genotype AA. 23909491 1449716072
OPRM1 rs1799971 G naltrexone efficacy yes A significant association was seen between the G allele and the likelihood of achieving a level of non-hazardous drinking (defined as drinking less than 14 standard drinks and having nor heavy drinking days in one week). However, no significant main effect was observed between rs1799971, naltrexone and either the weekly sum of standard drinks or the number of heavy drinking days. Allele G is associated with increased response to naltrexone in men with Alcoholism as compared to allele A. 24729984 1449188815
OPRM1 rs1799971 GG fentanyl dosage yes Genotype GG is associated with increased dose of fentanyl in women with Pain, Postoperative as compared to genotypes AA + AG. 29601950 1449716754
OPRM1 rs1799971 G morphine dosage no Allele G is not associated with dose of morphine in women with Pain, Postoperative as compared to allele A. 23431434 1449188786
OPRM1 rs1799971 G morphine dosage no Allele G is not associated with dose of morphine in people with Pain, Postoperative as compared to allele A. 29474345 1449172643
OPRM1 rs1799971 AG + GG morphine efficacy no A linear trend for higher doses of morphine to be associated with the G allele was observed but did not reach statistical significance due to the low frequency of the G allele in the study cohort. Genotypes AG + GG are not associated with dose of morphine in people with Pain, Postoperative as compared to genotype AA. 16580900 1449239780
OPRM1 rs1799971 G fentanyl dosage no Allele G is not associated with dose of fentanyl in people with Pain, Postoperative as compared to allele A. 23599738 1449716657
OPRM1 rs524731 A naltrexone efficacy no No significant association between this variant and smoking quit rate when naltrexone was used as augmentation to nicotine patch therapy. Allele A is not associated with response to naltrexone in people with Tobacco Use Disorder as compared to allele C. 31206155 1451113819
OPRM1 rs9479757 A naltrexone efficacy no No significant association between this variant and smoking quit rate when naltrexone was used as augmentation to nicotine patch therapy. Allele A is not associated with response to naltrexone in people with Tobacco Use Disorder as compared to allele G. 31206155 1451114020
OPRM1 rs1294092 G naltrexone efficacy no No significant association between this variant and smoking quit rate when naltrexone was used as augmentation to nicotine patch therapy. Allele G is not associated with response to naltrexone in people with Tobacco Use Disorder as compared to allele A. 31206155 1451113763
OPRM1 rs548646 T naltrexone efficacy no No significant association between this variant and smoking quit rate when naltrexone was used as augmentation to nicotine patch therapy. Please note that alleles have been complemented to the positive strand. Allele T is not associated with response to naltrexone in people with Tobacco Use Disorder as compared to allele C. 31206155 1451113832
OPRM1 rs9322447 G naltrexone efficacy no No significant association between this variant and smoking quit rate when naltrexone was used as augmentation to nicotine patch therapy. Allele G is not associated with response to naltrexone in people with Tobacco Use Disorder as compared to allele A. 31206155 1451113980
OPRM1 rs609148 A naltrexone efficacy no No significant association between this variant and smoking quit rate when naltrexone was used as augmentation to nicotine patch therapy. Allele A is not associated with response to naltrexone in people with Tobacco Use Disorder as compared to allele G. 31206155 1451113838
OPRM1 rs495491 G naltrexone efficacy no No significant association between this variant and smoking quit rate when naltrexone was used as augmentation to nicotine patch therapy. Allele G is not associated with response to naltrexone in people with Tobacco Use Disorder as compared to allele A. 31206155 1451113820
OPRM1 rs1799971 G ethanol other no No significant independent effects of OPRM1 genotype on subjective measures of alcohol response (SHAS, DEQ VAS, BAES or POMS). Allele G is not associated with response to ethanol in healthy individuals as compared to allele A. 28376280 1450826531
OPRM1 rs1799971 AA venlafaxine efficacy no This SNP was not associated with response or remission after 6 months of treatment with venlafaxine. Response and remission were assessed using the Hamilton Anxiety Scale (HAM-A) and the Clinical Global Impressions, improvement (CGI-I) score. Genotype AA is not associated with response to venlafaxine in people with Anxiety Disorders as compared to genotypes AG + GG. 23658070 1183703648
OPRM1 rs1799971 AG + GG naltrexone efficacy yes Genotypes AG + GG are associated with increased response to naltrexone in people with Alcoholism as compared to genotype AA. 18250251 769171526
OPRM1 rs1799971 AG + GG ethanol other yes Participants carrying the G allele had an increased frequency of drinking (nominally significant) and a trend towards a higher percentage of drinking days compared to participants with the AA genotype. Genotypes AG + GG are associated with increased exposure to ethanol in healthy individuals as compared to genotype AA. 25836994 1450821902
OPRM1 rs1799971 GG methadone "dosage","metabolism/PK" no Genotype GG is not associated with increased dose of methadone in people with Heroin Dependence as compared to genotype AA. 21902500 827816359
OPRM1 rs1799971 AG + GG ethanol metabolism/PK yes Individuals with the AG or GG genotype achieved significantly higher mean peak breath alcohol concentration as compared to those with the AA genotype. Those with the AG or GG genotype also showed significantly more post-priming drink requests compared to those with the AA genotype. Genotype accounted for 8% of the variance in peak breath alcohol concentration. Participants self-administered alcohol intravenously (6% ethanol solution) over a period of 2 hours. Genotypes AG + GG is associated with increased concentrations of ethanol in healthy individuals as compared to genotype AA. 25039301 1184748428
OPRM1 rs1799971 A methadone dosage no Methadone maintenance dose was not associated with genotype of the SNP but it was correlated to the highest dose ever used. Multiple doses versus single dose, body weight, history of cocaine dependence and ethnicity (Asian>Caucasian>African) were independently associated with methadone dose in multiple regression analysis. Allele A is not associated with dose of methadone in people with Opioid-Related Disorders as compared to allele G. 25556837 1444695419
OPRM1 rs1799971 G naltrexone efficacy no Patients with alcohol dependence and major depression received open-label and were randomized to citalopram or placebo. Allele G is not associated with response to naltrexone in people with Alcoholism and Depressive Disorder, Major. 25715171 1444697966
OPRM1 rs1799971 G naltrexone efficacy no The study found no genotype×treatment interaction on the primary outcome of heavy drinking (P=0.32). Allele G is not associated with response to naltrexone in people with Alcoholism as compared to allele A. 25760804 1444827662
OPRM1 rs1799971 G morphine "dosage","efficacy" no No association was observed between this variant and a patient's initial dose requirement or their need to escalate their dose of morphine. Allele G is not associated with dose of morphine in people with Pain as compared to allele A. 29259946 1449182322
OPRM1 rs1799971 AG + GG ethanol other yes Subjects carrying the G allele consumed significantly fewer drinks in an alcohol self-administration session than subjects with the AA genotype. Genotypes AG + GG are associated with decreased dose of ethanol as compared to genotype AA. 29265379 1450928686
OPRM1 rs1799971 AA codeine dosage yes Women who delivered via C-section and were prescribed codeine for postpartum pain. Prescribed "Tylenol #3" (300 mg acetaminophen and 30 mg codeine). Some women also prescribed naproxen. Those with the AA genotype consumed a lower mean dose of codeine as compared to those with the AG genotype. This SNP was found to significantly predict mean dose intake in multiple linear regression. The authors go on to note that this variant was not predictive of mean dose intake by Asians, though it was predictive of mean dose intake by Caucasians; this may be due to differences in allele frequencies between the two ethnicities. Genotype AA is associated with decreased dose of codeine in women as compared to genotype AG. 25752520 1446902603
OPRM1 rs1799971 AA acetaminophen efficacy yes Patients were receiving tramadol and acetaminophen as combination to relieve pain, specifically neuropathic pain associated with oxaliplatin treatment (as part of a FOLFOX or XELOX regimen) for adenocarcinoma. Genotype AA is associated with increased response to acetaminophen and tramadol in people with neuropathic pain as compared to genotypes AG + GG. 21837673 1446898218
OPRM1 rs1799971 G heroin toxicity no No association between this variant and heroin use in the last month. Allele G is not associated with dose of heroin in men Heroin Dependence as compared to allele A. 25911999 1450822015
OPRM1 rs1799971 AG + GG opioids dosage no This variant was not significant alone but patients with the combined OPRM1 118AG/GG (rs1799971) and COMT 472GG (rs4680) genotype required 50% higher dose increase for sufficient analgesia Genotypes AG + GG is associated with increased dose of opioids in people with Neoplasms and Pain as compared to genotype AA. 28745577 1448818810
OPRM1 rs1799971 GG oxycodone dosage yes Significant differences were seen between the GG genotype and AA + AG genotypes in the amount of oxycodone required to achieve the first state of adequate analgesia postsurgery and in baseline pain during movement. No significant difference was seen in total oxycodone consumption or in experimental heat and cold phenotypes. Genotype GG is associated with increased dose of oxycodone in women with Pain, Postoperative as compared to genotypes AA + AG. 25239082 1449000085
OPRM1 rs1799971 AA oxycodone dosage no Genotype AA is not associated with dose of oxycodone in people with Neoplasms as compared to genotypes AG + GG. 21209234 1449003091
OPRM1 rs1799971 G fentanyl efficacy no Variant was not associated with the rate of analgesic success of IV fentanyl in laboring women. However, the authors caution that the study was underpowered to provide firm conclusions. Allele G is not associated with response to fentanyl in women with as compared to allele A. 23302985 1449715215
OPRM1 rs1799971 GG morphine "dosage","efficacy" yes Patients with the GG genotype consumed more morphine in the first 24 hours after surgery than patients with the AA genotype. Note that the genotype frequencies in this cohort are not in Hardy-Weinberg equilibrium. Genotype GG is associated with increased dose of morphine in women with Pain, Postoperative as compared to genotype AA. 16871067 1449188859
OPRM1 rs1799971 AG + GG alfentanil metabolism/PK no Participants with the AG or GG genotypes required a 2.2x higher alfentanil concentration to reach a 50% increase in analgesia compared to participants with the AA genotype. Genotypes AG + GG are associated with decreased response to alfentanil in healthy individuals as compared to genotype AA. 16906017 1449715608
OPRM1 rs1799971 A ethanol "efficacy","toxicity" no Authors caution that the lack of observed association between rs1799971 and alcohol consumption may be due to differences in the study cohort, bias or a type II error. Allele A is not associated with response to ethanol in people with Alcoholism as compared to allele G. 22551036 1449161170
OPRM1 rs1799971 GG morphine "dosage","efficacy" no Low frequency of the GG genotype in the study cohort may have contributed to lack of statistical significance of this association. Genotype GG is not associated with dose of morphine in people with Pain, Postoperative as compared to genotypes AA + AG. 23686330 1449295820
OPRM1 rs1799971 G morphine "dosage","efficacy" no Linearity test showed a relationship between the number of G alleles and increasing morphine dose (i.e. AA < AG < GG). In addition, the haplotype of seven OPRM1 variants studied in this paper was significantly associated with morphine dose requirements (p=0.002). A stepwise backward linear regression model of age, rs9340799, rs1799971, rs4986936, rs1319339, rs174696, rs677830, rs4680, rs4818, and rs540825 was found to explain 10.7% of variance in morphine dose requirements in the study cohort (p=0.001) Allele G is not associated with dose of morphine in people with Pain, Postoperative as compared to allele A. 26902643 1449295851
OPRM1 rs1799971 GG fentanyl "dosage","efficacy" yes Patients with the GG genotype required almost twice as much fentanyl in the first 24 hours following surgery than patients with the AA genotype. Genotype GG is associated with increased dose of fentanyl in people with Pain, Postoperative as compared to genotype AA. 21174568 1449713783
OPRM1 rs1799971 AG + GG naloxone other yes Participants with the G allele had increased cortisol responses as a result of naloxone challenge than participants with the AA genotype. Genotypes AG + GG is associated with increased response to naloxone as compared to genotype AA. 16123758 1449188836
OPRM1 rs1799971 G fentanyl "dosage","efficacy" no rs1799971 genotype alone did not have a significant effect on fentanyl dose requirements in patients. However, there was a statistically significant effect on dose when rs1799971 genotype was combined with the presence or absence of the CYP3A4*18B allele. Allele G is not associated with dose of fentanyl in people with Pain, Postoperative as compared to allele A. 23313934 1449715307
OPRM1 rs1799971 G alfentanil metabolism/PK no Allele G is not associated with concentrations of alfentanil in healthy individuals as compared to allele A. 16906017 1449715602
OPRM1 rs1799971 AG + GG ethanol other not stated MRI study. Subjects carrying the G allele showed increased pre- vs. post-priming alcohol cue reactivity activation in the left caudate, thalamus, putamen, and bilateral supramarginal gyrus and parietal operculum cortex compared to subjects with the AA genotype. Genotypes AG + GG are associated with increased response to ethanol in people with Alcoholism as compared to genotype AA. 26125586 1450823384
OPRM1 rs1799971 AG + GG nicotine other yes The G allele was significantly associated with smoking behaviors in Caucasians but not in Asians. Genotypes AG + GG are associated with increased exposure to nicotine as compared to genotype GG. 26558451 1450823878
OPRM1 rs1799971 AG + GG nicotine efficacy yes Women carrying the G allele experienced a reduced relative reinforcing value of nicotine compared to women with the AA genotype. There was a significant interaction of rs1799971 genotype and gender as this association was not observed in male participants. Genotypes AG + GG are associated with decreased response to nicotine in women with Tobacco Use Disorder as compared to genotype AA. 16960700 1450811055
OPRM1 rs1799971 AG + GG nicotine efficacy no No significant difference in the relative reinforcing value of nicotine between genotype groups. Genotypes AG + GG are not associated with response to nicotine in men with Tobacco Use Disorder as compared to genotype AA. 16960700 1450811064
OPRM1 rs1799971 AG + GG naltrexone efficacy not stated From the paper: "In the naltrexone phase, but not in the placebo phase, smokers with the G allele had lower difference scores on liking than did other smokers." Genotypes AG + GG are associated with decreased response to naltrexone in people with Tobacco Use Disorder as compared to genotype AA. 16960700 1450811334
OPRM1 rs1799971 AG ethanol efficacy yes Subjects with the AG genotype showed significantly increased striatal dopamine release following administration of alcohol compared to AA subjects. Genotype AG is associated with increased response to ethanol in men as compared to genotype AA. 20479755 1450812854
OPRM1 rs1799971 GG opioids dosage not stated Only a subset of studies could be analyzed to determine the effect of the GG genotype on opioid dosing. When any study was removed from the analysis, the confidence interval included 0 and there were indications of publication bias within the subset. The authors note that these factors weaken the conclusion that the GG genotype is associated with increased opioid doses. Genotype GG is associated with increased dose of opioids in people with Pain as compared to genotypes AA + AG. 19683391 1450812447
OPRM1 rs1799971 AG + GG morphine efficacy no No significant difference in pain scores or administration of rescue medication in the first post operative 48 hours between the genotype groups. Genotypes AG + GG are not associated with response to morphine in women with Pain, Postoperative as compared to genotype AA. 28591085 1450826813
OPRM1 rs1799971 G fentanyl PD no There was no association between this variant and blood pressure, heart rate or QTc following fentanyl adminstration. Variant referred to as A118G in the paper. Allele G is not associated with response to fentanyl in healthy individuals as compared to allele A. 30281924 1450931716
OPRM1 rs1799971 AG + GG ethanol toxicity yes Subjects carrying the G allele had a significantly decreased odds ratio for reporting more heavy drinking days compared to subjects with the AA genotype. There was no significant association between rs1799971 and number of drinks per drinking day or number of drinking days. Genotypes AG + GG is associated with decreased exposure to ethanol in healthy individuals as compared to genotype AA. 28376280 1450826488
OPRM1 rs1799971 AG + GG ethanol other yes In a session of alcohol self-administration, subjects with the AG or GG genotypes had a greater initial increase in breath alcohol content (BrAC), faster BrAC increases over time and a smaller decline in BrAC at the end of the session. AG or GG subjects also reported engaging in heavy drinking more frequently than AA subjects. Genotypes AG + GG are associated with increased exposure to ethanol as compared to genotype AA. 27046326 1450824016
OPRM1 rs1799971 AG + GG nicotine other no Analysis of the total cohort found no significant difference in number of cigarettes smoked per day between genotype groups. Genotypes AG + GG are not associated with exposure to nicotine in people with Bipolar Disorder or Schizophrenia as compared to genotype AA. 28548579 1450826625
OPRM1 rs1799971 AG + GG nicotine other no Subgroup analysis of bipolar disorder patients only found no significant difference in number of cigarettes smoked per day between genotype groups. Genotypes AG + GG are not associated with exposure to nicotine in people with Bipolar Disorder as compared to genotype AA. 28548579 1450826733
OPRM1 rs1799971 G ethanol toxicity yes Participants with the G allele reported greater alcohol-induced stimulation, vigor and positive mood than participants with the AA genotype. Allele G is associated with increased response to ethanol in people with Alcoholism as compared to allele A. 23240711 1450814947
OPRM1 rs1799971 AG + GG ethanol dosage yes Women who carried the G allele were significantly less likely to be alcohol consumers than other groups. Genotypes AG + GG are associated with decreased dose of ethanol in women as compared to genotype AA. 26042510 1450822078
OPRM1 rs1799971 AG + GG opioids dosage yes Patients carrying the G allele had significantly higher opioid consumption in the first 24 hours post-surgery compared to those with the AA genotype. This significance was lost in the 48-hour postoperative period. Genotypes AG + GG are associated with increased dose of opioids in people with Pain, Postoperative as compared to genotype AA. 25794200 1450823183
OPRM1 rs1799971 AG + GG nicotine other yes Subgroup analysis of schizophrenia patients only found that those carrying the G allele smoked more cigarettes per day than those with the AA genotype. Genotypes AG + GG are associated with increased exposure to nicotine in people with Schizophrenia as compared to genotype AA. 28548579 1450826727
OPRM1 rs1799971 AG ethanol dosage no There was no significant difference in alcohol intake, craving or latency to access alcohol between the genotype groups in alcoholic subjects subjected to stress. Genotype AG is not associated with dose of ethanol in people with Alcoholism and Stress as compared to genotype AA. 19240053 1450812426
OPRM1 rs1799971 G opioids dosage no Allele G is not associated with dose of opioids in people with Pain as compared to allele A. 19683391 1450812440
OPRM1 rs1799971 G ethanol toxicity no There was no significant association between the G allele and subjective response to ethanol, craving, rate of binging or total alcohol exposure. Allele G is not associated with response to ethanol in healthy individuals as compared to allele A. 29497164 1450371982
OPRM1 rs1799971 AG + GG morphine "dosage","efficacy" yes Genotypes AG + GG are associated with increased dose of morphine in women with Pain, Postoperative as compared to genotype AA. 27649267 1450373388
OPRM1 rs1799971 G nicotine efficacy no No significant association between this variant and nicotine reward, perception, mood or reinforcement or physiological responses to nicotine. Allele G is not associated with response to nicotine in healthy individuals as compared to allele A. 18690117 1450812282
OPRM1 rs1799971 AG + GG ethanol efficacy yes Carriers of the G allele reported significantly higher vigor scores and significantly lower negative mood scores after drinking as compared with AA subjects. Genotypes AG + GG are associated with increased response to ethanol as compared to genotype AA. 20141248 1450812611
OPRM1 rs1799971 G heroin dosage no No significant difference in daily heroin intake between AA, AG or GG genotype groups. Allele G is not associated with dose of heroin in people with Heroin Dependence as compared to allele A. 11933204 1450808082
OPRM1 rs1799971 AG + GG nicotine dosage no No significant association between this variant and tobacco consumption. Genotypes AG + GG are not associated with dose of nicotine as compared to genotype AA. 26042510 1450822083
OPRM1 rs1799971 AG ethanol efficacy not stated MRI study. Participants with the AG genotype had increased activation within regions including the right insula, bilateral supramarginal gyri, left precuneus, right superior parietal lobule, right orbitofrontal cortex and right angular gyrus following an alcohol cue than AA participants. Genotype AG is associated with increased response to ethanol in people with Alcoholism as compared to genotype AA. 23876228 1450820473
OPRM1 rs1799971 AG + GG opioids "dosage","efficacy" yes In the primary analysis, patients carrying the G allele had higher opioid dose requirements than patients with the AA genotype. There was a gene-dose effect where opioid requirements increased with each copy of the G allele present. The authors note that there was significant heterogeneity in the primary analysis. The association retained its significance in subgroup analysis of Asian patients, but lost significance in Caucasian patients. Genotypes AG + GG are associated with increased dose of opioids in people with Pain, Postoperative as compared to genotype AA. 25102313 1450821136
OPRM1 rs1799971 AG ethanol other yes Individuals carrying the G allele had increased alcohol cue-induced activation in the left and right insulae, left dorsal striatum and right post- and precentral gyri compared the AA individuals. Genotype AG is associated with increased response to ethanol in people with Alcoholism as compared to genotype AA. 25937240 1450822034
OPRM1 rs1799971 AG + GG ethanol dosage no No significant association between this variant and drinking levels. Genotypes AG + GG are not associated with dose of ethanol as compared to genotype AA. 28273335 1450824453
OPRM1 rs1799971 G naltrexone efficacy no No significant association between this variant and smoking quit rate when naltrexone was used as augmentation to nicotine patch therapy. Allele G is not associated with response to naltrexone in people with Tobacco Use Disorder as compared to allele A. 31206155 1451113700
OPRM1 rs1799971 AG + GG opioids "dosage","efficacy" yes In the main analysis, presence of the G allele was significantly associated with increased opioid requirements across pain types. However, the authors note that there was significant heterogeneity. Significance of the association was maintained in subanaylsis of the postoperative pain group, but was lost in subanalysis of the cancer pain group. Genotypes AG + GG are associated with increased dose of opioids in people with Pain or Pain, Postoperative as compared to genotype AA. 31337162 1451118400
OPRM1 rs1799971 G oxycodone efficacy no No association between this variant and analgesic response to oxycodone, as assessed by cold pressor test, subjective effects of oxycodone. Allele G is not associated with response to oxycodone as compared to allele A. 31493434 1451121680
OPRM1 rs2075572 G ethanol efficacy yes Please note that alleles have been complemented to the positive strand. The G allele was associated with increased scores in the dizzy, drunk and nausea traits on the Subjective High Assessment Scale-Expectations (SHAS-E) questionnaire. Allele G is associated with increased response to ethanol as compared to allele C. 18433502 1450811856
OPRM1 rs2075572 C naltrexone efficacy no No significant association between this variant and smoking quit rate when naltrexone was used as augmentation to nicotine patch therapy. Allele C is not associated with response to naltrexone in people with Tobacco Use Disorder as compared to allele G. 31206155 1451113806